Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-4642 combination therapy in advanced colorectal cancer
ChiCTR2400094738Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Dec 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of HRS-4642 and SHR-9839 in colorectal cancer (CRC) (6 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoints: Objective response rate, Recommended Phase 2 Dose and 1 more. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
HRS-4642SHR-9839
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2400094738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094738.